image credit- shutterstock
Co-Diagnostics, Inc., a US-based molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, has announced that CoSara Diagnostics, the company's joint venture in India, has sent test kits of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the Centre for Cellular and Molecular Platforms (C-CAMP), an initiative supported by the Department of Biotechnology, Government of India.
The company has also announced successful completion of a proof-of-concept study evaluating an extraction-free Co-Primers® Ebola test on the Co-Dx PCR Pro® instrument using diluted plasma as a sample type. This feasibility work represents the first blood-borne assay designed for use on the PCR Pro point-of-care instrument.
The analytical studies, which are expected to support evaluation of the assay's limit of detection, repeatability, and reproducibility, were initiated following a request by C-CAMP for 200 of CoSara's Bundibugyo tests.
C-CAMP's InDx 2.0 National Diagnostics Catapult was launched in 2023 to proactively boost India's preparedness for current and future pandemics, by enabling and supporting the self-sufficiency and capabilities of the Indian diagnostics ecosystem.
CoSara is actively developing a second-generation pan-Ebola assay for broad-spectrum detection of Ebola species, in support of early laboratory confirmation, facilitating timely outbreak response, and strengthening detection capabilities in regions already at risk of Ebola virus outbreaks or that may become vulnerable in the future.
